Test environment running 7.6.6

Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C

Loading...
Thumbnail Image

Date

Authors

Yanjanin, N.M.
Velez, JI
Gropman, A.
King, K.
Bianconi,, S.E.
Conley, S.K.
Brewer, C.C.
Solomon, B.
Pavan, W.J.
Arcos-Burgos, Mauricio (Oscar)

Journal Title

Journal ISSN

Volume Title

Publisher

John Wiley & Sons Inc

Abstract

Niemann-Pick disease, type C is a neurodegenerative, lysosomal storage disorder with a broad clinical spectrumand a variable age of onset. The absence of a universally accepted clinical outcome measure is an impediment to the design of a therapeutic trial for NPC. Thus, we developed a clinical severity scale to characterize and quantify disease progression. Clinical signs and symptomsin nine major (ambulation, cognition, eye movement, fine motor, hearing, memory, seizures, speech, and swallowing) and eight minor (auditory brainstem response, behavior, gelastic cataplexy, hyperreflexia, incontinence, narcolepsy, psychiatric, and respiratory problems) domains were scored. Data were collected from 18 current NPC patients and were extracted from records of 19 patients. Both patient cohorts showed a linear increase in severity scores over time. Cross-sectional evaluation of current patients showed a linear increase in the severity score. Longitudinal chart review of historical data demonstrated that although age of onset varied significantly, the rate of progression appeared linear, independent of age of onset, and similar in all patients. Combining the data from both cohorts, disease progression could be modeled by the following equation: Ŝt0+x= Ŝ t0 + 1.87x; where Ŝt0 is the initial score and Ŝt0+x is the predicted future score after x years. Our observation that disease progression is similar across patients and independent of age of onset is consistent with a biphasic pathological model for NPC. This scale mayprove useful in the characterization of potential biomarkers, and as an outcome measure to monitor disease progression in NPC patients.

Description

Keywords

Citation

Source

American Journal of Medical Genetics, Part B: Neuropsychiatric

Book Title

Entity type

Access Statement

License Rights

Restricted until

2037-12-31